Antiviral therapyHumansMaleAdultAntiviral AgentsFemale
A Phase 1 study of the safety, tolerability, and pharmacokinetics of ALG-000184 (pevifoscorvir sodium), a novel Class E capsid assembly modulator, in healthy participants.
Ed Gane, Christian Schwabe, Min Wu, Tse-I Lin, Lawrence Blatt, John Fry, Sushmita Chanda, Kha Le
Published: 202510.1177/13596535251392955
Abstract
BackgroundClass E (empty) capsid assembly modulators (CAM-Es) inhibit HBV capsid assembly, pregenomic RNA encapsidation preventing formation the establishment of covalently closed circular HBV DNA (ccDNA). ALG-000184 (pevifoscorvir sodium), is a prod…
Preview only. Read the full abstract at the source